Indaba Capital Management, L.P. Esperion Therapeutics, Inc. Transaction History
Indaba Capital Management, L.P.
- $50.9 Million
- Q4 2024
A detailed history of Indaba Capital Management, L.P. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Indaba Capital Management, L.P. holds 3,000,000 shares of ESPR stock, worth $5.46 Million. This represents 12.97% of its overall portfolio holdings.
Number of Shares
3,000,000Holding current value
$5.46 Million% of portfolio
12.97%Shares
1 transactions
Others Institutions Holding ESPR
# of Institutions
215Shares Held
129MCall Options Held
1.78MPut Options Held
1.27M-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$44.6 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$25.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$18.1 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$11.5 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $121M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...